Support
DES-like vessel support*
Resorb
~95% of Magnesium is resorbed at 12 months1
Restore
Lowers the risk of neoatherosclerosis**, a known risk for scaffold thrombosis†
The three benefits of the Magmaris RMS technology directly translate into clinical results comparable to 2nd generation DES.
Target Lesion Failure (TLF)†† and Scaffold Thrombosis (ST) rates out to 36 months
TLF and ST rates in BIOSOLVE studies remain low and comparable to 2nd generation DES out to 36 months in similar patient population.
* Tested up to 28 days in pre-clinical trials.
** As demonstrated in pre-clinical studies.
† Very late.
†† TLF defined as a composite of cardiac death, Target-Vessel MI and Clinically-Driven TLR.
Support. Resorb. Restore.
DES-like vessel support.*
Magmaris acute recoil is comparable to modern DES6
No recoil increase is measured after one hour.7
The recoil rate is measured by calculating the difference between the diameter of the device at nominal pressure and the diameter of the device when no pressure is applied.
Similar mechanical properties translate into comparable clinical outcomes2,8
Multivariate adjustments showed that the device type was not an independent predictor of clinical adverse events.8
Propensity matched analysis comparing Magmaris to Orsiro at 12-month follow-up.
* Tested up to 28 days in pre-clinical trials.
† TLF defined as a composite of cardiac death, Target-Vessel MI and Clinically-Driven TLR.
Support. Resorb. Restore.
~95% of Magnesium resorbed at 12 months.1
Fast Magnesium resorption time
OCT post implantation9
Struts are well apposed to the vessel wall.
Struts are well apposed to the vessel wall.
OCT at 6 months9
Endothelialization progresses.
Endothelialization progresses.
OCT at 12 months9
The Magnesium resorption is almost completed.
The Magnesium resorption is almost completed.
OCT at 36 months9
The lumen is well preserved with a homogeneous surface.
The lumen is well preserved with a homogeneous surface.
Support. Resorb. Restore.
Magmaris has been shown to lower the risk of neoatherosclerosis**, a known risk for very late scaffold thrombosis.
55% less platelet coverage10
Magmaris and the custom-made stainless steel DES were implanted in a silicone tube and exposed to porcine blood flow for 1 hour.
The test was repeated with different positions for each device. After 1 hour, platelet coverage of the devices’ surfaces was analyzed by immunostaining.
Magmaris
DES**
Neoatherosclerosis† still a concern for the cardiology community
40% of patients who died 9 months after a DES implantation showed signs of neoatherosclerosis.11
* As demonstrated in pre-clinical studies.
** Custom-made stainless steel DES with the same Magmaris design and coating.
† Neoatherosclerosis is defined as the phenomenon of the transformation of stent neointima from normal neointima to an atherosclerotic lesion.
Formation of neoatherosclerosis
Device implantation
Endothelialization starts
Leaky endothelium allows macrophages and cholesterol infiltration
Foamy macrophages contribute to plaque development, e.g. neoatherosclerosis
Plaque ruptures eventually leading to device thrombosis
Magmaris exhibits greater endothelial integrity compared to a DES**, 12
In a rabbit model, Magmaris shows tightly formed endothelial cell junctions compared to a custom-made stainless steel DES**.
Tightly packed endothelial cells reduce macrophages and cholesterol infiltration which in turn potentially reduces the risk of neoatherosclerosis, a predictor of very late events.
Greater endothelial integrity is associated with lower macrophages infiltration.13
Magmaris
DES**
Arrow-heads indicate leaky endothelial junctions
Arrow-heads indicate leaky endothelial junctions
The accumulation of foamy macrophages in the neo-intimal space is an early sign of neoatherosclerosis.
Mean macrophage score reduction Magmaris vs. DES**: p < 0.0001
Magmaris
DES**
Magmaris significantly reduces the mean neoatherosclerosis score compared to a DES**, 12
Mean neoatherosclerosis score reduction Magmaris vs. DES**:
p < 0.0001
The neoatherosclerosis score was assessed by histology and determines the quantity of foam cells in different layers of the neointima.
Confidence through evidence
Magmaris |
24 months (First Cohort) BIOSOLVE-IV14 (n=1,071) 6.6%TLF* |
0.5%**Definite/probable scaffold thrombosis |
|
36 months BIOSOLVE-II/III15 (n=174) 6.3%TLF* |
0.0%Definite/probable scaffold thrombosis |
|
|
60 months BIOSOLVE-II3 (n=121) 8.0%TLF* |
0.0%Definite/probable scaffold thrombosis |
|
Precursor |
36 months BIOSOLVE-I16 (n=46) 6.6%TLF* |
0.0%Definite/probable scaffold thrombosis |
Magmaris shows a favorable healing profile and little progression of atherosclerosis over time.
36 months BIOSOLVE-II17 (n=21)
Progression
3
patientsRegression
4
patientsStable
14
patientsProgression/regression defined as +/- 5% change from baseline
* Target Lesion Failure. Composite of cardiac and unknown death, Target-Vessel Myocardial Infarction, Clinically-Driven Target Lesion revascularization and emergent CABG.
** Four out of five cases having early antiplatelet or anticoagulant interruption at post procedure.
1. Joner M, Ruppelt P, Zumstein P, et al. Preclinical Evaluation of Degradation Kinetics and Elemental Mapping of First and Second Generation Bioresorbable Magnesium Scaffolds. EuroIntervention. 2018 Feb 20. pii: EIJ-D-17-00708. doi: 10.4244/EIJ-D-17-00708; 2. Haude M, Ince H, Kische S, et al. Safety and Clinical Performance of the Drug Eluting Absorbable Metal Scaffold in the Treatment of Subjects with de Novo Lesions in Native Coronary Arteries at 12-month follow-up- BIOSOLVE-II and BIOSOLVE-III. Journal of the American College of Cardiology. 2017; 70(18). DOI: 10.1016/j.jacc.2017.09.071; 3. Haude M, Ince H, Kische S, et al. Sustained safety and performance of the second-generation sirolimus-eluting absorbable metal scaffold: Pooled outcomes of the BIOSOLVE-II and -III trials at 3 years. Cardiovascular Revascularization Medicine. 2020. doi: 10.1016/j.carrev.2020.04.006; 4. Stone, G. Everolimus-Eluting Stents: SPIRIT and PLATINUM Update. Presented at: TCT; Oct 22-26, 2012; Miami, USA. ClinicalTrials.gov: NCT00180310 .NCT00180479, NCT00307047; 5. EVOLVE FHU 24m: Meredith I, Verheye S, Weissmann N, et al. Six-month IVUS and two-year clinical outcomes in the EVOLVE FHU trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent. EuroIntervention. 2013; 9: 308-315; 6. BIOTRONIK data on file; 7. Schmidt W, Behrens P, Brandt-Wunderlich C, et al. In vitro performance investigation of bioresorbable scaffolds - Standard tests for vascular stents and beyond. Cardiovasc Revasc Med. 2016;17(6):375-83. doi: 10.1016/j.carrev.2016.05.001; 8. Hideo-Kajita A, Garcia-Garcia H, Azizi V. Comparison of Clinical Outcomes Between Magmaris (Dreams 2G) and Orsiro Drug Eluting Stent: Pooled Patient Level Analysis From Biosolve II-III and Bioflow II Trials. Presented at ACC; March 10, 2018; Orlando, USA; 9. BIOSOLVE-II case, GER443-012. Courtesy of M. Haude, Lukaskrankenhaus Neuss, Germany 2015; 10. Lipinski MJ, Acampado E, Cheng Q, et al.Comparison of Acute Thrombogenicity for Magnesium versus Stainless Steel Stents in a Porcine Arteriovenous Shunt Model. EuroIntervention. 2018 May 8. pii: EIJ-D-17-00958. doi: 10.4244/EIJ-D-17-00958; 11. Nakazawa G, Vorpahl M, Finn M, et al. One Step Forward and Two Steps Back With Drug-Eluting-Stents. JACC: Cardiovascular Imaging . 2009; 2(5): 625-628. DOI: 10.1016/j.jcmg.2009.01.011; 12. Joner M. Systemic vs Site Targeted Treatment of Neoatherosclerosis. Presented at: ESC; Aug 28, 2017; Barcelona, Spain; 13. Andreou I, Stone P. In-Stent Atherosclerosis at a Crossroads. Neoatherosclerosis or Paleoatherosclerosis? Circulation. 2016;134:1413–1415. DOI: 10.1161/CIRCULATIONAHA.116.025129; 14. Torzewski J. Safety and performance of Magmaris at 24-month follow-up of BIOSOLVE-IV. Presented at: eEuroPCR; 2021; virtual congress. ClinicalTrials.gov: NCT02817802; 15. Haude M. Long-term clinical data of the BIOSOLVE-II study with the drug-eluting absorbable metal scaffold in the treatment of subjects with de novo lesions in native coronary arteries - BIOSOLVE-II. Presented at: e-Course PCR, 25.June 2020, Paris, France, NCT01960504; 16. Haude M, Erbel R, Ernep, et al. Safety and performance of the Drug-Eluting Absorbable Metal Scaffold (DREAMS) in patients with de novo coronary lesions: 3-year results of the prospective, multicenter, first-in-man BIOSOLVE-I trial. EuroIntervention. 2016; 12: e160-e166 .doi: 10.4244/EIJY16M06_01; 17. Joner M. Magmaris: Reducing the risk of neoatherosclerosis. Presented at: TCT; Sep 22, 2018; San Diego, USA.
BIOSOLVE-I,- II and -IV based on Kaplan-Meier failure estimate analysis including censored observations. The pooled analysis of BIOSOLVE-II and -III based on frequency analysis.
Magmaris is a trademark or registered trademark of the BIOTRONIK Group of Companies. Xience is a trademark or registered trademark of the Abbott Group of Companies. Synergy is a trademark or a registered trademark of the Boston Scientific Group of Companies.
Magmaris is currently not available in the US.
© 2021 BIOTRONIK AG – All rights reserved.
Specifications are subject to modification, revision and improvement.